Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TPST |
---|---|---|
09:32 ET | 1275 | 1.32 |
09:34 ET | 1815 | 1.3396 |
09:36 ET | 124 | 1.34 |
09:38 ET | 100 | 1.32 |
09:41 ET | 224 | 1.31 |
09:43 ET | 300 | 1.311285 |
09:45 ET | 200 | 1.31 |
09:48 ET | 100 | 1.315 |
09:50 ET | 5544 | 1.31 |
09:54 ET | 288 | 1.305 |
09:56 ET | 827 | 1.3 |
09:59 ET | 700 | 1.31 |
10:01 ET | 1000 | 1.31 |
10:03 ET | 300 | 1.3105 |
10:06 ET | 896 | 1.3 |
10:10 ET | 3924 | 1.305 |
10:12 ET | 553 | 1.3095 |
10:14 ET | 100 | 1.3 |
10:19 ET | 280 | 1.3095 |
10:24 ET | 100 | 1.3 |
10:26 ET | 6400 | 1.315 |
10:28 ET | 1799 | 1.33 |
10:30 ET | 200 | 1.33 |
10:32 ET | 400 | 1.33 |
10:33 ET | 2600 | 1.3202 |
10:37 ET | 788 | 1.3201 |
10:44 ET | 200 | 1.33 |
10:55 ET | 100 | 1.33 |
11:00 ET | 5910 | 1.335 |
11:02 ET | 200 | 1.33 |
11:08 ET | 100 | 1.32 |
11:11 ET | 1131 | 1.33 |
11:15 ET | 2749 | 1.34 |
11:18 ET | 100 | 1.345 |
11:20 ET | 800 | 1.345 |
11:22 ET | 10203 | 1.35 |
11:24 ET | 2000 | 1.3581 |
11:27 ET | 1000 | 1.3597 |
11:29 ET | 32061 | 1.375 |
11:31 ET | 2011 | 1.37 |
11:33 ET | 100 | 1.36 |
11:36 ET | 6720 | 1.3605 |
11:38 ET | 100 | 1.365 |
11:40 ET | 100 | 1.36 |
11:42 ET | 2401 | 1.36 |
11:44 ET | 3000 | 1.355 |
11:45 ET | 100 | 1.35 |
11:47 ET | 200 | 1.355 |
11:51 ET | 200 | 1.35 |
11:54 ET | 100 | 1.35 |
11:56 ET | 200 | 1.35 |
11:58 ET | 100 | 1.35 |
12:00 ET | 200 | 1.35 |
12:02 ET | 200 | 1.35 |
12:03 ET | 100 | 1.35 |
12:05 ET | 300 | 1.355 |
12:07 ET | 100 | 1.35 |
12:09 ET | 5010 | 1.345 |
12:12 ET | 100 | 1.34 |
12:14 ET | 955 | 1.34 |
12:18 ET | 200 | 1.335 |
12:20 ET | 300 | 1.335 |
12:21 ET | 127 | 1.335 |
12:23 ET | 100 | 1.335 |
12:27 ET | 200 | 1.335 |
12:34 ET | 583 | 1.3301 |
12:36 ET | 200 | 1.3385 |
12:39 ET | 4183 | 1.3301 |
12:41 ET | 100 | 1.33 |
12:45 ET | 414 | 1.34 |
12:48 ET | 100 | 1.33 |
12:50 ET | 1077 | 1.33 |
12:52 ET | 1254 | 1.335 |
12:54 ET | 100 | 1.325 |
12:56 ET | 114 | 1.32 |
01:06 ET | 100 | 1.32 |
01:08 ET | 100 | 1.32 |
01:10 ET | 300 | 1.32 |
01:12 ET | 200 | 1.32 |
01:14 ET | 100 | 1.32 |
01:15 ET | 100 | 1.32 |
01:17 ET | 200 | 1.32 |
01:19 ET | 200 | 1.32 |
01:21 ET | 6411 | 1.34 |
01:28 ET | 200 | 1.335 |
01:32 ET | 1065 | 1.335 |
01:33 ET | 100 | 1.3312 |
01:35 ET | 100 | 1.33 |
01:37 ET | 100 | 1.33 |
01:39 ET | 300 | 1.335 |
01:42 ET | 890 | 1.33 |
01:44 ET | 100 | 1.33 |
01:46 ET | 309 | 1.33 |
01:48 ET | 100 | 1.33 |
01:50 ET | 400 | 1.33 |
01:53 ET | 100 | 1.33 |
01:55 ET | 500 | 1.33 |
01:57 ET | 2000 | 1.33 |
02:04 ET | 100 | 1.33 |
02:06 ET | 200 | 1.33 |
02:08 ET | 200 | 1.33 |
02:09 ET | 300 | 1.33 |
02:11 ET | 810 | 1.33 |
02:13 ET | 1900 | 1.34 |
02:26 ET | 100 | 1.345 |
02:27 ET | 5000 | 1.3499 |
02:31 ET | 2969 | 1.35 |
02:33 ET | 100 | 1.35 |
02:36 ET | 100 | 1.355 |
02:38 ET | 5000 | 1.3594 |
02:42 ET | 2500 | 1.3564 |
02:45 ET | 2136 | 1.365 |
02:47 ET | 100 | 1.365 |
02:51 ET | 500 | 1.3692 |
02:54 ET | 400 | 1.3601 |
03:00 ET | 100 | 1.36 |
03:02 ET | 100 | 1.365 |
03:03 ET | 1250 | 1.37 |
03:05 ET | 100 | 1.36 |
03:12 ET | 100 | 1.36 |
03:18 ET | 100 | 1.36 |
03:20 ET | 252 | 1.3605 |
03:21 ET | 100 | 1.36 |
03:27 ET | 250 | 1.36 |
03:30 ET | 100 | 1.3601 |
03:32 ET | 3600 | 1.3615 |
03:34 ET | 200 | 1.36 |
03:38 ET | 100 | 1.36 |
03:41 ET | 300 | 1.365 |
03:45 ET | 2100 | 1.36 |
03:48 ET | 700 | 1.3601 |
03:50 ET | 100 | 1.36 |
03:52 ET | 200 | 1.36 |
03:54 ET | 334 | 1.36 |
03:56 ET | 100 | 1.36 |
03:57 ET | 961 | 1.36 |
03:59 ET | 35240 | 1.37 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Tempest Therapeutics Inc | 32.8M | -0.8x | --- |
Xilio Therapeutics Inc | 33.1M | -0.4x | --- |
Surrozen Inc | 33.1M | -0.5x | --- |
Ocean Biomedical Inc | 32.2M | -0.3x | --- |
Acurx Pharmaceuticals Inc | 32.0M | -1.7x | --- |
LianBio | 31.9M | -0.4x | --- |
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $32.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 25.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.84 |
EPS | $-1.64 |
Book Value | $1.21 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.